Hlib Chabaniuk

Solid Biosciences Inc. spotlights Patrick González SGT-003 insights at major DMD conference

Solid Biosciences Inc. spotlights Patrick González SGT-003 insights at major DMD conference
Solid Biosciences unveils SGT-003 therapy

Solid Biosciences Inc. presented its next-generation gene therapy candidate, SGT-003, for Duchenne muscular dystrophy (DMD) during a high-profile Clinical Trials session last week.

Patrick González, PhD, Vice President and Head of Clinical Science at the company, shared key insights into the therapy's potential, reinforcing Solid Biosciences Inc.'s commitment to advancing treatment options for DMD. The presentation took place at a leading clinical and scientific congress focused on muscular dystrophy, strengthening industry interest in innovative approaches to address this rare genetic disorder.

Solid Biosciences Inc. recently co-hosted a webinar with Defeat Duchenne to discuss the clinical development of SGT-003 gene therapy. The company also highlighted advances in targeted genetic therapy delivery at a Boston biotech conference earlier this year. These initiatives demonstrate Solid Biosciences’ ongoing engagement with clinical and scientific communities focused on Duchenne muscular dystrophy.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.